

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5390808

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
IRX THERAPEUTICS, INC.		11/06/2018
RECEIVING PARTY DATA		
Name:	BROOKLYN IMMUNOTHERAPEUTICS LLC	
Street Address:	654 MADISON AVENUE, SUITE 1601	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10065	
PROPERTY NUMBERS Total: 15		
Property Type	Number	
Patent Number:	9333238	
Patent Number:	9931378	
Patent Number:	7993660	
Patent Number:	8591956	
Patent Number:	8470562	
Patent Number:	9539320	
Patent Number:	9566331	
Patent Number:	7731945	
Patent Number:	6977072	
Patent Number:	7153499	
Patent Number:	8784796	
Patent Number:	9789172	
Patent Number:	9789173	
Patent Number:	9492517	
Patent Number:	9492519	
CORRESPONDENCE DATA		
Fax Number:	(617)646-8646	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-646-8000	

Email: patents_AmyM@wolfgreenfield.com
Correspondent Name: AMY MCMAHON KROM
Address Line 1: 600 ATLANTIC AVENUE
Address Line 2: WOLF GREENFIELD
Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	U0157.70000US01
--------------------------------	-----------------

NAME OF SUBMITTER:	AMY MCMAHON KROM
---------------------------	------------------

SIGNATURE:	/Amy McMahon Krom/
-------------------	--------------------

DATE SIGNED:	02/25/2019
---------------------	------------

Total Attachments: 9

source=U015770000US01-CASI-AM#page1.tif
source=U015770000US01-CASI-AM#page2.tif
source=U015770000US01-CASI-AM#page3.tif
source=U015770000US01-CASI-AM#page4.tif
source=U015770000US01-CASI-AM#page5.tif
source=U015770000US01-CASI-AM#page6.tif
source=U015770000US01-CASI-AM#page7.tif
source=U015770000US01-CASI-AM#page8.tif
source=U015770000US01-CASI-AM#page9.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (“**IP Assignment**”), dated as of November 6, 2018, is made by IRX Therapeutics, Inc., a Delaware corporation (“**Seller**”), located at 654 Madison Avenue, Suite 1601, New York, New York 10065, in favor of Brooklyn Immunotherapeutics LLC, a Delaware limited liability company (“**Buyer**”), located at c/o Ara Partners, 109 North Post Oak Lane, Suite 530, Houston, TX 77024, the purchaser of certain assets of Seller pursuant to the Asset Purchase Agreement between Buyer and Seller, dated as of the date hereof (the “**Asset Purchase Agreement**”).

WHEREAS, under the terms of the Asset Purchase Agreement, Seller has conveyed, transferred, and assigned to Buyer, among other assets, certain intellectual property of Seller, and has agreed to execute and deliver this IP Assignment, for recording with the United States Patent and Trademark Office, and corresponding entities or agencies in any applicable jurisdictions;

NOW THEREFORE, the parties agree as follows:

1. Assignment. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby irrevocably conveys, transfers, and assigns to Buyer, and Buyer hereby accepts, all of Seller’s right, title, and interest in and to the following (the “**Assigned IP**”):

(a) the patents and patent applications set forth on Schedule 1 hereto and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals thereof (the “**Patents**”);

(b) all rights of any kind whatsoever of Seller accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(c) any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(d) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation and Further Actions. Seller hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this IP Assignment upon request by Buyer. Following the date hereof, upon Buyer’s reasonable request, and at Buyer’s sole cost and expense, Seller shall take such steps and actions, and provide such cooperation and assistance to Buyer and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be necessary to effect, evidence, or perfect the assignment of the Assigned IP to Buyer, or any assignee or successor thereto.

3. Terms of the Asset Purchase Agreement. The parties hereto acknowledge and agree that this IP Assignment is entered into pursuant to the Asset Purchase Agreement, to which reference is made for a further statement of the rights and obligations of Seller and Buyer with respect to the Assigned IP. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase Agreement shall govern.

4. Counterparts. This IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same agreement. A signed copy of this IP Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this IP Assignment.

5. Successors and Assigns. This IP Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. Governing Law. This IP Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this IP Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Seller has duly executed and delivered this IP Assignment as of the date first above written.

IRX THERAPEUTICS, INC.



By: _____

Name: Mark Leuchtenberger

Title: Chairman, President and CEO

Address for Notices:

654 Madison Avenue, Suite 1601


New York, New York 10065

E-mail: markl@irxtherapeutics.com

Attention: Mark Leuchtenberger

AGREED TO AND ACCEPTED:

BROOKLYN IMMUNOTHERAPEUTICS
LLC

By: 

Name: Charles R. Cherington

Title: Manager

Address for Notices:

c/o Ara Partners

109 North Post Oak Lane, Suite 530

Houston, TX 77024

E-mail: charles@arapartners.com

Attention: Charles R. Cherington

SCHEDULE 1
ASSIGNED PATENTS AND PATENT APPLICATIONS

DOES NOT INCLUDE EXPIRED PROVISIONALS, EXPIRED PATENTS OR ABANDONED APPLICATIONS

As of 10/2/2018

WGS Case Number	Country	SubCase	Country Name	Title	Status	Owner	Application Number	Filing Date	Patent Number	Issue Date
U0157.70000	AU	00	Australia	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	2010328197	8-Dec-10	2010328197	29-Oct-15
U0157.70000	BE	00	Belgium	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	CA	00	Canada	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	2820202	8-Dec-10	2820202	12-Jun-18
U0157.70000	CH	00	Switzerland	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	CN	01	China (People's Republic)	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Published	IRX	201710091427.0	8-Dec-10		
U0157.70000	DE	00	Germany	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	602010048539.0	14-Feb-18
U0157.70000	DK	00	Denmark	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	EP	00	European Patent	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	ES	00	Spain	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	E10836605	14-Feb-18
U0157.70000	FI	00	Finland	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	FR	00	France	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	GB	00	United Kingdom	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	HK	01	Hong Kong	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Published	IRX	18100051.6	8-Dec-10		
U0157.70000	IT	00	Italy	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	502018000012928	14-Feb-18
U0157.70000	JP	00	Japan	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	2012-543241	8-Dec-10	5889797	26-Feb-16
U0157.70000	LI	00	Liechtenstein	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	NL	00	Netherlands	METHOD OF REVERSING IMMUNE SUPPRESSION OF LANGERHANS CELLS	Granted	IRX	10836605.5	8-Dec-10	2510106	14-Feb-18
U0157.70000	US	01	United States of America	METHOD OF IMMUNOTHERAPY FOR TREATMENT OF HUMAN PAPILLOMAVIRUS INFECTION	Granted	IRX	13/514688	8-Jun-12	9333238	10-May-16
U0157.70000	US	02	United States of America	METHOD OF IMMUNOTHERAPY FOR TREATMENT OF HUMAN PAPILLOMAVIRUS INFECTION	Granted	IRX	15/097693	13-Apr-16	9931378	3-Apr-18
U0157.70005	AU	00	Australia	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	2008329741	26-Nov-08	2008329741	24-Dec-13
U0157.70005	BE	00	Belgium	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	CA	00	Canada	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Pending	IRX	2706445	26-Nov-08		
U0157.70005	CH	00	Switzerland	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	DE	00	Germany	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	DK	00	Denmark	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	EP	00	European Patent	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	ES	00	Spain	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	FI	00	Finland	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	FR	00	France	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	GB	00	United Kingdom	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08	2234642	27-Sep-17
U0157.70005	HK	00	Hong Kong	INHIBITION OF APOPTOSIS OF T CELLS BY NCM	Published	IRX	11103474.6	26-Nov-08		

U0157.70005	IT	00	Italy	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08 502017000149097	27-Sep-17
U0157.70005	JP	00	Japan	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	2010-536148	26-Nov-08 5563472	20-Jun-14
U0157.70005	LI	00	Liechtenstein	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08 2234642	27-Sep-17
U0157.70005	NL	00	Netherlands	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	08854580.1	26-Nov-08 2234642	27-Sep-17
U0157.70005	US	01	United States of America	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	12/323595	26-Nov-08 7993660	9-Aug-11
U0157.70005	US	02	United States of America	METHOD OF INCREASING IMMUNOLOGICAL EFFECT	Granted	IRX	13/205229	8-Aug-11 8591956	26-Nov-13
U0157.70006	AU	00	Australia	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	2009244617	14-Apr-09 2009244617	24-May-14
U0157.70006	BE	00	Belgium	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	CA	00	Canada	PRIMARY CELL DERIVED BIOLOGIC MODIFIED MANUFACTURING PROCESS	Granted	IRX	2758834	14-Apr-09 2758834	7-Nov-17
U0157.70006	CH	00	Switzerland	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	DE	00	Germany	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 602009017625.0	31-Jul-13
U0157.70006	DK	00	Denmark	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	EP	00	European Patent Convention	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	ES	00	Spain	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	FI	00	Finland	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	FR	00	France	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	GB	00	United Kingdom	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	IT	00	Italy	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	JP	00	Japan	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	2011-504242	14-Apr-09 5647601	14-Nov-14
U0157.70006	LI	00	Liechtenstein	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	MX	00	Mexico	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	9	14-Apr-09 319271	10-Apr-14
U0157.70006	NL	00	Netherlands	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	SE	00	Sweden	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 2276850	31-Jul-13
U0157.70006	TR	00	Turkey	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	09743225.6	14-Apr-09 TR 2013 11544 T4	31-Jul-13
U0157.70006	US	01	United States of America	IRX-2 MODIFIED MANUFACTURING PROCESS	Granted	IRX	12/423601	14-Apr-09 8470562	25-Jun-13
U0157.70008	AU	00	Australia	VACCINE IMMUNOTHERAPY	Granted	IRX	2010248761	17-May-10 2010248761	26-May-16
U0157.70008	AU	01	Australia	VACCINE IMMUNOTHERAPY	Granted	IRX	2013203561	17-May-10 2013203561	10-Mar-16
U0157.70008	BE	00	Belgium	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	CA	00	Canada	VACCINE IMMUNOTHERAPY	Allowed	IRX	2799081	17-May-10	
U0157.70008	CH	00	Switzerland	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	DE	00	Germany	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	DK	00	Denmark	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	EP	00	European Patent Convention	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	ES	00	Spain	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	FI	00	Finland	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	FR	00	France	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	GB	00	United Kingdom	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18

U0157.70008	HK	00	Hong Kong	VACCINE IMMUNOTHERAPY	Published	IRX	12109265.5	17-May-10	18-Apr-18
U0157.70008	IT	00	Italy	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	28-Aug-15
U0157.70008	JP	00	Japan	VACCINE IMMUNOTHERAPY	Granted	IRX	2012-511064	17-May-10 5797190	18-Apr-18
U0157.70008	LI	00	Liechtenstein	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	NL	00	Netherlands	VACCINE IMMUNOTHERAPY	Granted	IRX	10775661.1	17-May-10 2429585	18-Apr-18
U0157.70008	US	01	United States of America	VACCINE IMMUNOTHERAPY	Granted	IRX	13/320584	15-Nov-11 9539320	10-Jan-17
U0157.70008	US	02	United States of America	VACCINE IMMUNOTHERAPY	Granted	IRX	13/771622	20-Feb-13 9566331	14-Feb-17
U0157.70012	US	01	United States of America	METHOD TO DIAGNOSE AND MONITOR CELLULAR IMMUNE DEFICIENCIES	Granted	USF*	09/529566	2-Jun-00 6482389	*This case is licensed by IRX 19-Nov-02 by IRX 8-Nov-07
U0157.70014	AU	00	Australia	IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION	Granted	IRX	2002342151	26-Oct-02 2002342151	
U0157.70014	US	01	United States of America	IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION	Granted	IRX	10/280627	26-Oct-02 7731945	8-Jun-10
U0157.70015	AU	01	Australia	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	2007203505	26-Oct-01 2007203505	4-Nov-10
U0157.70015	CA	00	Canada	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	2464228	26-Oct-01 2464228	17-Jan-17
U0157.70015	CA	01	Canada	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Allowed	IRX	2950109	26-Oct-01	
U0157.70015	JP	02	Japan	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	2012-020558	26-Oct-01 5930742	13-May-16
U0157.70015	JP	03	Japan	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	2013-14029	26-Oct-01 5963688	8-Jul-16
U0157.70015	US	01	United States of America	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	10/015123	26-Oct-01 6977072	20-Dec-05
U0157.70015	US	02	United States of America	VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	10/430506	5-May-03 7153499	26-Dec-06
U0157.70015	US	06	United States of America	VACCINE IMMUNOTHERAPY FOR TREATING HEPATOCELLULAR CANCER IN IMMUNE SUPPRESSED PATIENTS	Granted	IRX	13/940579	12-Jul-13 8784796	22-Jul-14
U0157.70015	US	07	United States of America	VACCINE IMMUNOTHERAPY FOR TREATING LYMPHOMA IN IMMUNE SUPPRESSED PATIENTS	Granted	IRX	14/295598	4-Jun-14 9789172	17-Oct-17
U0157.70015	US	08	United States of America	VACCINE IMMUNOTHERAPY FOR TREATING CERVICAL CANCER IN IMMUNE SUPPRESSED PATIENTS	Granted	IRX	14/295660	4-Jun-14 9789173	17-Oct-17
U0157.70018	AU	00	Australia	VACCINE IMMUNOTHERAPY	Granted	IRX	2007276835	24-Jul-07 2007276835	17-Jul-13
U0157.70018	CA	00	Canada	COMPOSITIONS AND METHODS FOR TREATMENT OF ADVANCED PROSTATE CANCER	Granted	IRX	2694428	24-Jul-07 2694428	12-Jun-18
U0157.70018	EP	01	Convention	A COMPOSITION FOR TREATMENT OF ADVANCED PROSTATE CANCER	Published	IRX	13188131.0	24-Jul-07	
U0157.70018	HK	01	Hong Kong	A COMPOSITION FOR TREATMENT OF ADVANCED PROSTATE CANCER	Published	IRX	14107132.8	24-Jul-07	
U0157.70018	JP	02	Japan	VACCINE IMMUNOTHERAPY	Granted	IRX	2015-222533	24-Jul-07 6162778	23-Jun-17
U0157.70018	US	01	United States of America	VACCINE IMMUNOTHERAPY	Granted	IRX	12/374732	8-Oct-09 9492517	15-Nov-16
U0157.70018	US	02	United States of America	VACCINE IMMUNOTHERAPY	Granted	IRX	13/940635	12-Jul-13 9492519	15-Nov-16

U0157.70019	BE	00	Belgium	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	CH	00	Switzerland	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	DE	00	Germany	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 602007026173.2	17-Oct-12
U0157.70019	EP	00	European Patent Convention	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	ES	00	Spain	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 ES2397854T3	17-Oct-12
U0157.70019	FR	00	France	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	GB	00	United Kingdom	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	IT	00	Italy	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 193966E/2013	17-Oct-12
U0157.70019	LI	00	Liechtenstein	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70019	NL	00	Netherlands	IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS	Granted	IRX	07797158.8	9-Mar-07 1998811	17-Oct-12
U0157.70032	WO	00	Patent Cooperation Treaty	USES OF PD-1/PD-L1 INHIBITORS AND/OR CTLA-4 INHIBITORS WITH A BIOLOGIC CONTAINING MULTIPLE CYTOKINE COMPONENTS TO TREAT CANCER	Published	IRX	PCT/US2017/0474 77	18-Aug-17	